Cargando…
CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia
Induced pluripotent stem cells (iPSC) offer a unique opportunity for developmental studies, disease modeling and regenerative medicine approaches in humans. The aim of our study was to create an in vitro ‘patient-specific cell-based system' that could facilitate the screening of new therapeutic...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824678/ https://www.ncbi.nlm.nih.gov/pubmed/24113177 http://dx.doi.org/10.1038/cddis.2013.369 |
_version_ | 1782290729063677952 |
---|---|
author | Di Pasquale, E Lodola, F Miragoli, M Denegri, M Avelino-Cruz, J E Buonocore, M Nakahama, H Portararo, P Bloise, R Napolitano, C Condorelli, G Priori, S G |
author_facet | Di Pasquale, E Lodola, F Miragoli, M Denegri, M Avelino-Cruz, J E Buonocore, M Nakahama, H Portararo, P Bloise, R Napolitano, C Condorelli, G Priori, S G |
author_sort | Di Pasquale, E |
collection | PubMed |
description | Induced pluripotent stem cells (iPSC) offer a unique opportunity for developmental studies, disease modeling and regenerative medicine approaches in humans. The aim of our study was to create an in vitro ‘patient-specific cell-based system' that could facilitate the screening of new therapeutic molecules for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited form of fatal arrhythmia. Here, we report the development of a cardiac model of CPVT through the generation of iPSC from a CPVT patient carrying a heterozygous mutation in the cardiac ryanodine receptor gene (RyR2) and their subsequent differentiation into cardiomyocytes (CMs). Whole-cell patch-clamp and intracellular electrical recordings of spontaneously beating cells revealed the presence of delayed afterdepolarizations (DADs) in CPVT-CMs, both in resting conditions and after β-adrenergic stimulation, resembling the cardiac phenotype of the patients. Furthermore, treatment with KN-93 (2-[N-(2-hydroxyethyl)]-N-(4methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), an antiarrhythmic drug that inhibits Ca(2+)/calmodulin-dependent serine–threonine protein kinase II (CaMKII), drastically reduced the presence of DADs in CVPT-CMs, rescuing the arrhythmic phenotype induced by catecholaminergic stress. In addition, intracellular calcium transient measurements on 3D beating clusters by fast resolution optical mapping showed that CPVT clusters developed multiple calcium transients, whereas in the wild-type clusters, only single initiations were detected. Such instability is aggravated in the presence of isoproterenol and is attenuated by KN-93. As seen in our RyR2 knock-in CPVT mice, the antiarrhythmic effect of KN-93 is confirmed in these human iPSC-derived cardiac cells, supporting the role of this in vitro system for drug screening and optimization of clinical treatment strategies. |
format | Online Article Text |
id | pubmed-3824678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-38246782013-11-12 CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia Di Pasquale, E Lodola, F Miragoli, M Denegri, M Avelino-Cruz, J E Buonocore, M Nakahama, H Portararo, P Bloise, R Napolitano, C Condorelli, G Priori, S G Cell Death Dis Original Article Induced pluripotent stem cells (iPSC) offer a unique opportunity for developmental studies, disease modeling and regenerative medicine approaches in humans. The aim of our study was to create an in vitro ‘patient-specific cell-based system' that could facilitate the screening of new therapeutic molecules for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited form of fatal arrhythmia. Here, we report the development of a cardiac model of CPVT through the generation of iPSC from a CPVT patient carrying a heterozygous mutation in the cardiac ryanodine receptor gene (RyR2) and their subsequent differentiation into cardiomyocytes (CMs). Whole-cell patch-clamp and intracellular electrical recordings of spontaneously beating cells revealed the presence of delayed afterdepolarizations (DADs) in CPVT-CMs, both in resting conditions and after β-adrenergic stimulation, resembling the cardiac phenotype of the patients. Furthermore, treatment with KN-93 (2-[N-(2-hydroxyethyl)]-N-(4methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), an antiarrhythmic drug that inhibits Ca(2+)/calmodulin-dependent serine–threonine protein kinase II (CaMKII), drastically reduced the presence of DADs in CVPT-CMs, rescuing the arrhythmic phenotype induced by catecholaminergic stress. In addition, intracellular calcium transient measurements on 3D beating clusters by fast resolution optical mapping showed that CPVT clusters developed multiple calcium transients, whereas in the wild-type clusters, only single initiations were detected. Such instability is aggravated in the presence of isoproterenol and is attenuated by KN-93. As seen in our RyR2 knock-in CPVT mice, the antiarrhythmic effect of KN-93 is confirmed in these human iPSC-derived cardiac cells, supporting the role of this in vitro system for drug screening and optimization of clinical treatment strategies. Nature Publishing Group 2013-10 2013-10-10 /pmc/articles/PMC3824678/ /pubmed/24113177 http://dx.doi.org/10.1038/cddis.2013.369 Text en Copyright © 2013 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Original Article Di Pasquale, E Lodola, F Miragoli, M Denegri, M Avelino-Cruz, J E Buonocore, M Nakahama, H Portararo, P Bloise, R Napolitano, C Condorelli, G Priori, S G CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia |
title | CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia |
title_full | CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia |
title_fullStr | CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia |
title_full_unstemmed | CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia |
title_short | CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia |
title_sort | camkii inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824678/ https://www.ncbi.nlm.nih.gov/pubmed/24113177 http://dx.doi.org/10.1038/cddis.2013.369 |
work_keys_str_mv | AT dipasqualee camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia AT lodolaf camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia AT miragolim camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia AT denegrim camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia AT avelinocruzje camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia AT buonocorem camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia AT nakahamah camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia AT portararop camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia AT bloiser camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia AT napolitanoc camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia AT condorellig camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia AT priorisg camkiiinhibitionrectifiesarrhythmicphenotypeinapatientspecificmodelofcatecholaminergicpolymorphicventriculartachycardia |